person · Reporting owner

Hatfield Jeffrey S.

Disclosed activity across 6 companies

Tapewire entity: 43527
SEC CIK: 0001609879

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INVIVO THERAPEUTICS HOLDINGS CORP.NVIV · Entity 94539	Director	January 19, 2018	January 23, 2018
Larimar Therapeutics, Inc.ZFGN · Entity 5634	Director · Chief Executive Officer	January 22, 2019	January 25, 2019
Vir Biotechnology, Inc.VIR · Entity 4522	Director	May 27, 2026	May 28, 2026
Viridian Therapeutics, Inc.\DEVRDN · Entity 4316	Director	February 04, 2021	February 08, 2021
aTYR PHARMA INCLIFE · Entity 7233	Director	May 06, 2020	May 08, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INVIVO THERAPEUTICS HOLDINGS CORP.

Report date January 19, 2018 · Filed January 23, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2028-01-19	Direct	12,500	Reported balance After 2018-01-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-01-19 · Grant · Acquired 12,500 · Balance 12,500 F1: The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date.

Larimar Therapeutics, Inc.

Report date January 22, 2019 · Filed January 25, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2029-01-22	Direct	525,000	Reported balance After 2019-01-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-01-22 · Grant · Acquired 525,000 · Balance 525,000 F1: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months.

Vir Biotechnology, Inc.

Report date May 27, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	39,806	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 8,000 · Balance 39,806 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-05-26	Direct	16,000	Reported balance After 2026-05-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-27 · Grant · Acquired 16,000 · Balance 16,000 F3: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

F2: The RSUs will vest in full on May 27, 2027.

F3: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Viridian Therapeutics, Inc.\DE

Report date February 04, 2021 · Filed February 08, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.50 · Expires 2031-02-04	Direct	25,000	Reported balance After 2021-02-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-02-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board.

Filing footnotes · ownership attribution and instrument terms

F1: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board.

aTYR PHARMA INC

Report date May 06, 2020 · Filed May 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2030-05-06	Direct	1,428	Reported balance After 2020-05-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-05-06 · Grant · Acquired 1,428 · Balance 1,428 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Vitae Pharmaceuticals, Inc

Report date October 24, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	244,996	Reported balance After 2016-10-24 transaction · row 1 1 source row Row 1 · 2016-10-24 · Other · Disposed 244,996 · Balance 244,996 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Augusta Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Company's Common Stock for $21.00 per share (the "Offer Price"), without any interest and subject to any tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at 12:00 midnight, New York City time, at the end of October 24, 2016, Merger Subsidiary accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2017-07-24	Direct	0	Reported balance After 2016-10-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-25 · Disposition to issuer · Disposed 26,086 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which represented the vested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2017-09-25	Direct	0	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 30,434 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2018-01-29	Direct	0	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Disposition to issuer · Disposed 6,245 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F5: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2019-01-20	Direct	0	Reported balance After 2016-10-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-25 · Disposition to issuer · Disposed 20,869 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F6: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2020-03-23	Direct	0	Reported balance After 2016-10-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-10-25 · Disposition to issuer · Disposed 10,320 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F7: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2021-03-22	Direct	0	Reported balance After 2016-10-25 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-10-25 · Disposition to issuer · Disposed 134,782 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F8: This option, which represented the unvested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.40 · Expires 2025-02-13	Direct	0	Reported balance After 2016-10-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-10-25 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F9: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2025-08-14	Direct	0	Reported balance After 2016-10-25 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2016-10-25 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F10: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2026-02-15	Direct	0	Reported balance After 2016-10-25 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2016-10-25 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F11: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2026-08-14	Direct	0	Reported balance After 2016-10-25 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2016-10-25 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F12: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Augusta Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Company's Common Stock for $21.00 per share (the "Offer Price"), without any interest and subject to any tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at 12:00 midnight, New York City time, at the end of October 24, 2016, Merger Subsidiary accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F3: This option, which represented the vested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F4: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F5: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F6: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F7: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F8: This option, which represented the unvested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F9: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F10: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F11: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F12: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 27, 2026 Filed May 28, 2026 23:24 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $9.10	$0.00	Disclosure SEC source: 0001628280-26-038963 · wk-form4_1780010671.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-05-26 F3 · shares: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027. Read SEC document
May 27, 2026 Filed May 28, 2026 23:24 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001628280-26-038963 · wk-form4_1780010671.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,806 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 27, 2027. Read SEC document
May 30, 2025 Filed Jun 2, 2025 23:20 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $4.94	$0.00	Disclosure SEC source: 0001628280-25-028892 · wk-form4_1748906445.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-29 F3 · shares: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026. Read SEC document
May 30, 2025 Filed Jun 2, 2025 23:20 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001628280-25-028892 · wk-form4_1748906445.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,806 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 30, 2026. Read SEC document
May 30, 2024 Filed Jun 3, 2024 15:59 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $10.39	$0.00	Disclosure SEC source: 0001628280-24-026193 · wk-form4_1717430363.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-05-29 Read SEC document
May 30, 2024 Filed Jun 3, 2024 15:59 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-026193 · wk-form4_1717430363.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,806 Read SEC document
May 22, 2023 Filed May 24, 2023 18:34 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	12,054	$0.00 Strike: $25.74	$0.00	Disclosure SEC source: 0001209191-23-031841 · doc4.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,054 Underlying: Common Stock · 12,054 shares Expires 2033-05-21 Read SEC document
May 22, 2023 Filed May 24, 2023 18:34 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	6,027	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031841 · doc4.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,806 Read SEC document
May 23, 2022 Filed May 25, 2022 21:51 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	12,810	$0.00 Strike: $24.14	$0.00	Disclosure SEC source: 0001209191-22-031949 · doc4.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,810 Underlying: Common Stock · 12,810 shares Expires 2032-05-22 Read SEC document
May 23, 2022 Filed May 25, 2022 21:51 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	6,405	$0.00	$0.00	Disclosure SEC source: 0001209191-22-031949 · doc4.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,779 Read SEC document
May 21, 2021 Filed May 25, 2021 20:35 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	6,748	$0.00 Strike: $45.28	$0.00	Disclosure SEC source: 0001209191-21-035706 · doc4.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,748 Underlying: Common Stock · 6,748 shares Expires 2031-05-20 Read SEC document
May 21, 2021 Filed May 25, 2021 20:35 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantCommon Stock	3,374	$0.00	$0.00	Disclosure SEC source: 0001209191-21-035706 · doc4.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,374 Read SEC document
February 04, 2021 Filed Feb 8, 2021 22:40 UTC	Viridian Therapeutics, Inc.\DE VRDN · Entity 4316	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $20.50	$0.00	Disclosure SEC source: 0000899243-21-005208 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document
December 09, 2020 Filed Dec 11, 2020 21:42 UTC	Vir Biotechnology, Inc. VIR · Entity 4522	GrantStock Option (Right to Buy) · Derivative	46,500	$0.00 Strike: $29.43	$0.00	Disclosure SEC source: 0001209191-20-062955 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2030-12-08 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on December 9, 2021, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document
May 21, 2020 Filed May 22, 2020 21:35 UTC	Viridian Therapeutics, Inc.\DE MGEN · Entity 4316	GrantStock Option (right to buy) · Derivative	24,000	$0.00 Strike: $0.63	$0.00	Disclosure SEC source: 0001209191-20-031843 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document
May 06, 2020 Filed May 8, 2020 21:02 UTC	aTYR PHARMA INC LIFE · Entity 7233	GrantStock Option (right to buy) · Derivative	1,428	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001209191-20-027974 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document
June 19, 2019 Filed Jun 21, 2019 21:14 UTC	Viridian Therapeutics, Inc.\DE MGEN · Entity 4316	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $2.36	$0.00	Disclosure SEC source: 0001209191-19-038561 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document
May 08, 2019 Filed May 10, 2019 21:22 UTC	aTYR PHARMA INC LIFE · Entity 7233	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $0.58	$0.00	Disclosure SEC source: 0001209191-19-029039 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document
January 22, 2019 Filed Jan 25, 2019 01:25 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	525,000	$0.00 Strike: $4.63	$0.00	Disclosure SEC source: 0000899243-19-001927 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. Read SEC document
June 27, 2018 Filed Jun 28, 2018 20:38 UTC	Viridian Therapeutics, Inc.\DE MGEN · Entity 4316	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $6.46	$0.00	Disclosure SEC source: 0001209191-18-039879 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-06-26 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document
May 15, 2018 Filed May 17, 2018 20:27 UTC	aTYR PHARMA INC LIFE · Entity 7233	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-18-030915 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document
February 22, 2018 Filed Feb 23, 2018 22:00 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	275,000	$0.00 Strike: $7.77	$0.00	Disclosure SEC source: 0000899243-18-005333 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-02-22 F1 · derivative.exercise_date: 25% of this option vests on February 22, 2019, and the remainder vests in equal monthly installments thereafter over 36 months. Read SEC document
January 19, 2018 Filed Jan 23, 2018 21:22 UTC	INVIVO THERAPEUTICS HOLDINGS CORP. NVIV · Entity 94539	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $0.69	$0.00	Disclosure SEC source: 0001179110-18-001044 · edgar.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-19 F1 · derivative.exercise_date: The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date. Read SEC document
December 29, 2017 Filed Dec 29, 2017 21:30 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	1,100,000	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-17-029728 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Stock · 1,100,000 shares Expires 2027-10-09 F1 · date: This option was granted on October 9, 2017, subject to vesting based on the Issuer's stock price appreciation and certain financial performance goals. The financial performance goals were waived on December 29, 2017 and therefore the option is deemed a reportable derivative security as of such date. F2 · derivative.exercise_date: The option vests and becomes exercisable based on the Issuer's common stock price during the two years after the first anniversary of the date of grant as follows: 25% of shares subject to the option vest after the stock price is equal to or greater than $10.00 per share for 20 consecutive trading days; and an additional 6.25% of the shares subject to the option vest for every additional $2.50 in stock price above $10.00 per share for 20 consecutive trading days. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). Read SEC document
October 09, 2017 Filed Oct 11, 2017 22:13 UTC	Larimar Therapeutics, Inc. ZFGN · Entity 5634	GrantStock Option (Right to Buy) · Derivative	550,000	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-17-024054 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: 25% of this option vests on October 9, 2018 and the remainder vests in equal monthly installments thereafter over a 3-year period. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). Read SEC document
May 09, 2017 Filed May 11, 2017 23:01 UTC	aTYR PHARMA INC LIFE · Entity 7233	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $3.15	$0.00	Disclosure SEC source: 0001209191-17-031640 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document
April 03, 2017 Filed Apr 4, 2017 20:07 UTC	aTYR PHARMA INC LIFE · Entity 7233	GrantStock Option (right to buy) · Derivative	32,000	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001209191-17-024676 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning May 3, 2017, such that this option will be fully exercisable on April 3, 2020, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document
November 01, 2016 Filed Nov 3, 2016 19:13 UTC	INVIVO THERAPEUTICS HOLDINGS CORP. NVIV · Entity 94539	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $4.25	$0.00	Disclosure SEC source: 0001179110-16-031183 · edgar.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-11-01 F1 · derivative.exercise_date: This option vests in 24 equal installments on each monthly anniversary of the date of grant until fully vested on the 24-month anniversary of the date of grant. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	60,000	$12.22 Strike: $8.78	$733,200.00	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 11 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-08-14 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F12 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	60,000	$12.42 Strike: $8.58	$745,200.00	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 10 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-02-15 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F11 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	50,000	$12.72 Strike: $8.28	$636,000.00	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 9 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-08-14 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F10 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	50,000	$6.60 Strike: $14.40	$330,000.00	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 8 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-02-13 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F9 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	134,782	$13.87 Strike: $7.13	$1,869,426.34	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 7 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 134,782 shares Expires 2021-03-22 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F8 · derivative.exercise_date: This option, which represented the unvested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	10,320	$14.10 Strike: $6.90	$145,512.00	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 6 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,320 shares Expires 2020-03-23 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F7 · derivative.exercise_date: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	20,869	$17.09 Strike: $3.91	$356,651.21	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 5 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,869 shares Expires 2019-01-20 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F6 · derivative.exercise_date: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	6,245	$17.09 Strike: $3.91	$106,727.05	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 4 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,245 shares Expires 2018-01-29 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F5 · derivative.exercise_date: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	30,434	$17.55 Strike: $3.45	$534,116.70	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 3 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,434 shares Expires 2017-09-25 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4 · derivative.exercise_date: This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	26,086	$17.55 Strike: $3.45	$457,809.30	Disclosure SEC source: 0001104659-16-151945 · a4.xml · derivative · entry 2 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,086 shares Expires 2017-07-24 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which represented the vested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
October 24, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	OtherCommon Stock	244,996	$21.00	$5,144,916.00	Disclosure SEC source: 0001104659-16-151945 · a4.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,996 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Augusta Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Company's Common Stock for $21.00 per share (the "Offer Price"), without any interest and subject to any tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at 12:00 midnight, New York City time, at the end of October 24, 2016, Merger Subsidiary accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. Read SEC document
September 14, 2016 Filed Sep 16, 2016 17:00 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	SaleCommon Stock	50,000	$20.81	$1,040,500.00	Disclosure SEC source: 0001104659-16-145191 · a4.xml · nonDerivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,996 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2015. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.